{
    "nctId": "NCT06172088",
    "briefTitle": "Exploratory Study Therapeutic Fasting Reduce Physical Limitations, Quality of Life During Aromatase Inhibitor Therapy",
    "officialTitle": "Exploratory Study of Therapeutic Fasting to Reduce Limitations in Physical Well-being and Quality of Life During Endocrine Therapy With Aromatase Inhibitors",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer Patients Treated With Aromatase Inhibitors",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 54,
    "primaryOutcomeMeasure": "Numerical rating scale",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with curatively treated hormone receptor positive breast cancer who have been on aromatase inhibitors (AI) therapy for at least 3 months and have significant Pain (NRS\\>4).\n* Informed consent.\n\nExclusion Criteria:\n\n* Eating disorders.\n* Permanent medication other than endocrine therapy, which would constitute an absolute or relative contraindication to outpatient fasting, such as Marcumar, lithium, Antiepileptic drugs, etc.\n* Patients with diabetes mellitus type 1 or 2\n* Uncontrolled cerebral seizure disorder.\n* Participation in another diet/fasting study.\n* Lack of willingness to store and share personal medical data within the framework of the protocol.\n* Insufficient knowledge of the German language.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}